Ligand News and Research

RSS
Argonne researchers awarded 65 million hours of computing time on Blue Gene/P supercomputer

Argonne researchers awarded 65 million hours of computing time on Blue Gene/P supercomputer

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

Study sheds light on poorly understood aspect of interaction of HIV with natural killer cells

Ligand reverse stock split becomes effective

Ligand reverse stock split becomes effective

Discovery could provide new approaches to treat metabolic disorders

Discovery could provide new approaches to treat metabolic disorders

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

GPR124 protein controls growth of blood vessels into brains

GPR124 protein controls growth of blood vessels into brains

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

Amgen wins Scrip Best New Drug award for Prolia

Amgen wins Scrip Best New Drug award for Prolia

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

GSK's Revolade receives Japanese approval for treatment of chronic ITP

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

Omeros to develop new drugs for major diseases

Omeros to develop new drugs for major diseases

First in vivo screening system for complete human nuclear hormone receptor family

First in vivo screening system for complete human nuclear hormone receptor family

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Scripps Research study findings could transform drug development to produce more effective treatments

Scripps Research study findings could transform drug development to produce more effective treatments

Scientists use NMR technology to improve protein purification in drug development

Scientists use NMR technology to improve protein purification in drug development

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx presents CCX140 clinical data at EASD

Prostate cancer - TRAIL is worth a trial

Prostate cancer - TRAIL is worth a trial